Question 1

What is Chonluten in research terms?

Accepted Answer

Chonluten is a synthetic tripeptide, Glu-Asp-Gly (research designation T-34), and one of the 'Khavinson ultrashort peptide' bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology; in the literature it is described as associated with bronchial/respiratory epithelial tissue. It is handled here as a Research Use Only material, not a product for human use.

Question 2

How robust is the peer-reviewed evidence for Chonluten?

Accepted Answer

Limited. PubMed indexes essentially one study with Chonluten-specific data (an in vitro cell-culture experiment; Avolio et al., 2022, Int J Mol Sci; PMID 35408963; doi:10.3390/ijms23073607). No animal or human studies specific to this tripeptide were found, and most other information online is vendor-generated rather than peer-reviewed.

Question 3

What did that single in vitro study actually observe?

Accepted Answer

In human THP-1 monocytes/macrophages at 100 ng/mL, Chonluten reduced LPS-stimulated TNF and IL-6 release and increased ERK1/2 phosphorylation. These are cell-culture observations shared with several related peptides; they characterize behavior in a dish and do not demonstrate any clinical or in-vivo outcome (Avolio et al., 2022; PMID 35408963; doi:10.3390/ijms23073607).

Question 4

Does Chonluten support lung or respiratory function?

Accepted Answer

Indexed primary research does not establish respiratory or regenerative outcomes for Chonluten. A common point of confusion: the lung-cell differentiation gene effects reported in the Khavinson literature belong to a different peptide, the tetrapeptide AEDL (Bronchogen), not to Chonluten (EDG) (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053). This is an open research gap rather than an established effect.

Question 5

What is the proposed mechanism of action?

Accepted Answer

The Khavinson framework proposes that ultrashort peptides can enter cells and modulate gene expression (for example, interactions with DNA or histones). For Chonluten specifically, this mechanism is hypothetical and has not been characterized in indexed literature; the gene-regulation evidence in this peptide family comes from other members (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053).

Question 6

What about dosing in research protocols?

Accepted Answer

No validated dosing exists, and no human dosing guidance can be provided. Research-reported amounts vary and appear mainly in non-peer-reviewed sources; the one indexed study used 100 ng/mL in cell culture, which does not translate to any in-vivo or human amount. Refer to the relevant protocol reference for any research-use parameters. This is not medical advice.

Question 7

Are there safety or observed-effects data?

Accepted Answer

No peer-reviewed safety, tolerability, or observed-effects data specific to Chonluten in animals or humans were identified. Observed effects in research are confined to the in vitro cell-culture context described above. As an RUO material, it is not intended for human or veterinary use.

Phase	Daily reference amount	Units / volume
Weeks 1–2	250 mcg (0.25 mg)	3.75 units (0.0375 mL)
Weeks 3–4	500 mcg (0.5 mg)	7.5 units (0.075 mL)
Weeks 5–6	1,000 mcg (1 mg)	15 units (0.15 mL)
Weeks 7–8	1,500 mcg (1.5 mg)	22.5 units (0.225 mL)
Weeks 9–10	2,000 mcg (2 mg)	30 units (0.30 mL)
Weeks 11–12	3,000 mcg (3 mg)	45 units (0.45 mL)
Weeks 13–14	4,000 mcg (4 mg)	60 units (0.60 mL)
Weeks 15–16	4,000 mcg (4 mg)	60 units (0.60 mL)

Chonluten.

Calculated volume reference

Cited protocol & reconstitution guide